Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 0.70 |
| ▸ | ITGB7 | P26010 | 20/20 | 0.70 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512416 | 1.00 | ITGA4 (0.70) | ITGA4ITGB7ITGB1 | |
| SCHEMBL4522314 | 0.90 | ITGA4 (0.66) | ITGA4ITGB7ITGB1 | |
| SCHEMBL4522316 | 0.90 | ITGA4 (0.66) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24946013 | 0.83 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL6029683 | 0.82 | ITGA4 (0.76) | ITGA4ITGB7ITGB1 | |
| SCHEMBL8281604 | 0.82 | ITGA4 (0.76) | ITGA4ITGB7ITGB1 | |
| SCHEMBL7535841 | 0.81 | ITGA4 (0.47) | ITGA4ITGB7ITGB1 | |
| SCHEMBL31481676 | 0.81 | ITGA4 (0.55) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945903 | 0.80 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL5211422 | 0.79 | ITGA4 (0.82) | ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618983-B2 | Bicyclic triazole α4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| EP-1720839-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-15 | — | — | US | disclosed |
| WO-2006052962-A2 | BICYCLIC TRIAZOLE A4 INTEGRIN INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128748-A1 | Bicyclic triazole alpha4 integrin inhibitors | ITGA4, ITGB4, ITGB5 | ITGA4 1/4885ITGB7 12/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.